Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

Monday, February 22, 2016 10:00 AM UTC

HEIDELBERG, Germany, Feb. 22, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CMO, Jens-Peter Marschner, will present at the symposium titled "Emerging Approaches in Cancer Immunotherapy" in New York City on Monday, February 29 at 12:10-12:40 pm Eastern Standard Time. The symposium will be presented as part of the New York Academy of Sciences' Cancer and Signaling Discussion Group, which provides a forum for scientists from academia, industry, and government, as well as other stakeholders, to come together to explore cutting-edge topics in the field. A live webcast of Affimed's presentation will be available through the New York Academy of Sciences' website at www.nyas.org.

About Affimed N.V.

Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.

CONTACT: IR Contact:
         Caroline Stewart, Head of IR
         Phone: +1 347394 6793
         E-Mail: [email protected] or [email protected]
         
         Media Contact:
         Anca Alexandru, Head of Communications
         Phone: +49 6221 64793341
         E-Mail: [email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

Editor's Picks

Welcome to EconoTimes